Rezolute Prices $100M Offering at $3.87/Share, Led by Frazier Life Sciences
RZLT has more than doubled off its 52-week low of $1.07.
Summary
Rezolute priced a roughly $100 million underwritten offering at $3.87 per share (22.0 million shares plus 3.8 million pre-funded warrants), led by Frazier Life Sciences, with closing expected around November 16, 2026.
Key Events · Financing and Capital Events · RZLT
-
Offering Priced at $3.87 per Share
The offering comprises 22,040,976 common shares at $3.87 plus pre-funded warrants for up to 3,800,000 shares at $3.869 each, for gross proceeds of approximately $100 million.
-
Dilution Adds ~25.8M Shares
22,040,976 shares plus 3,800,000 pre-funded warrant shares equals roughly 25.8 million new shares, against a $4.19 stock price and a $374.3 million market cap.
-
Frazier Life Sciences Leads Financing
Frazier Life Sciences led the transaction with participation from new and existing funds; Morgan Stanley, Guggenheim and Cantor are joint book-running managers.
-
Proceeds Fund Commercialization Prep
Net proceeds, together with existing cash, will fund ersodetug commercialization preparation, working capital and general corporate purposes.
Analysis · RZLT · Life Sciences
Rezolute has priced a $100 million raise at $3.87 per share, a modest discount to today's $4.19 quote, and the stock is already down sharply after the sunRIZE trial missed its primary endpoint on November 2. The cash matters: $90.0 million at the end of the September quarter plus roughly $100 million gross extends the runway well past the mid-December 2026 upLIFT topline readout, which is the next binary event. The cost is dilution — 22.0 million shares plus 3.8 million pre-funded warrants against a stock trading near $4 — but the participation of Frazier Life Sciences alongside new and existing funds is the offsetting vote of confidence in ersodetug.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RZLT was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $374.3M. The 52-week trading range was $1.07 to $11.17. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.